Alnylam Q3 Losses Up as R&D Costs Increase

For the three-month period ended Sept. 30, Alnylam's net loss climbed to $9.6 million, or $0.23 per share, from $9.2 million, or $0.22 per share, in the same period a year earlier.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.